Skip to main content

Table 3 Comparison of 1 year treatment response between the strategic treatment group and unmatched treatment group

From: Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Variables Strategic treatment (n=17) mismatched (n=17) p-value
Month 6
TJC (M6-BL) − 6 (− 8, − 4.5) − 5 (− 11, − 2.5) 0.9172
SJC (M6-BL) − 4 (− 7, − 2) − 4 (− 10.5, − 2) 0.8086
DAPSA (M6-BL) − 18.6 (− 27.3, − 13.7) − 18.4 (− 32.4, − 13.3) 0.9314
% decrease, SDAI − 77.7 (− 89.9, − 71.4) − 74.0 (− 82.3, − 53.2 0.1432
Proportion of REM, n (%) 7 (41.1) 3 (17.6) 0.2587
Proportion of REM/LDA, n (%) 17 (100) 14 (82.3) 0.1136
Minimal Disease Activity 12 (70.6) 4 (25.3) 0.0075*
% improvement, PASI 86.0 (53.1, 100) 100 (17.6, 100) 0.9809
PASI90, n (%) 7/15 (46.7) 9/14 (64.2) 0.9469
PASI75, n (%) 7/15 (46.7) 9/14 (64.2) 0.9469
Month 12
TJC (M12-BL) − 6 (− 8.5, − 3) − 5 (− 11.5, − 2) 0.9175
SJC (M12-BL) − 4 (− 6, − 1.5) − 5 (− 11.5, − 2) 0.4365
DAPSA − 18.4 (− 27.3, − 12.9) − 19.45 (− 33.6, − 10.5) 0.8228
% decrease, DAPSA (M12) − 87.4 (− 97.1, − 75.4) − 72.0 (− 89.2, − 44.7) 0.0605
Proportion of REM, n (%) 10 (58.8) 4 (25.3) *0.0399*
Proportion of REM/LDA, n (%) 15 (88.2) 13 (76.4) 0.3281
Minimal Disease Activity 14 (82.3) 7 (41.2) *0.0162*
% improvement, PASI 92.7 (51.7, 100) 100 (72.7, 100) 0.3794
PASI90, n (%) 9/15 (60) 10/14 (71.4) 0.8502
PASI75, n (%) 9/15 (60) 11/14 (78.5) 0.9320
  1. Data are expressed as median (interquartile range [IQR] ) or number (%)
  2. TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, TJC tender joint counts 68, SJC swollen joint counts 66, DAPSA Disease Activity in Psoriatic Arthritis, LDA low disease activity, REM remission, PASI Psoriasis Area and Severity Index
  3. *p<0.05, by Mann-Whitney U test or chi-square test